AstraZeneca DESTINY-PanTumor02 (HER2+ Tumors) - Clinical Trial

What is the Purpose of this Study?

We are doing this research study to understand the effectiveness and safety of trastuzumab deruxtecan (T-DXd) on select HER2-expressing tumors (tumors that have a specific protein on their surface).

What is the Condition Being Studied?

Advanced solid tumors that express HER2

Who Can Participate in the Study?

Adults with the following advanced solid tumors that express HER2
-Biliary tract cancer
-Bladder cancer
-Cervical cancer
-Endometrial cancer
-Ovarian cancer
-Rare tumors (excluding breast, non-small cell lung cancer, gastric cancer, and colorectal cancer

Age Group

What is Involved?

If you choose to join this study you will:
-Have an infusion of the study drug (trastuzumab deruxtecan) once every 3 weeks
-Provide old tumor tissue
-Have an eye exam
-Have physical exams, blood and urine tests
-Have imaging scans (CT and/or MRI)

Study Details

Full Title
A Phase II, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Trastuzumab Deruxtecan (T-DXd, DS-8201a) for the Treatment of Selected HER2-expressing Tumors (DESTINY-PanTumor02)
Principal Investigator
Medical Oncologist
Protocol Number
IRB: PRO00107117
NCT: NCT04482309
Phase II
Enrollment Status
Open for Enrollment
Contact the Duke Recruitment Innovation Center